Brown–Forman vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Brown family-controlled spirits company; Jack Daniel's world's best-selling American whiskey; $4.2B FY2024 revenue; Woodford Reserve premium bourbon; EU tariff risk for ~60% international volumes.
About
Brown-Forman Corporation is one of the largest American-owned spirits and wine companies in the world, founded in 1870 by George Garvin Brown in Louisville, Kentucky, and still controlled by the Brown family, who own a majority of voting shares. The company trades on NYSE (BF-B for Class B shares) and generated approximately $4.2 billion in net sales for fiscal year 2024 (ending April 30, 2024) under CEO Lawson Whiting. Brown-Forman's crown jewel, Jack Daniel's Tennessee Whiskey, remains the world's best-selling American whiskey brand, complemented by a premium portfolio including Woodford Reserve (super-premium bourbon), Old Forester (the original bonded bourbon), Herradura and El Jimador tequilas, Benriach and GlenDronach single malt Scotches, and Diplomático rum.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.